Abstract: The present invention provides a composition comprising a GLP-1 receptor agonist and a glucagon receptor agonist and an application of the composition. More specifically, the present invention provides a pharmaceutical composition comprising a pharmaceutically effective amount of the GLP-1 receptor agonist and the glucagon receptor agonist, wherein the GLP-1 receptor agonist and the glucagon receptor agonist independently form a conjugate with a hydrophilic polymer, or the GLP-1 receptor agonist and the glucagon receptor agonist jointly form a conjugate with the hydrophilic polymer.
Type:
Grant
Filed:
December 28, 2016
Date of Patent:
January 19, 2021
Assignee:
PEGBIO CO., LTD.
Inventors:
Michael Min Xu, Wei Lv, Yinghui Zhang, Xiaosu Luo
Abstract: The present invention provides a composition comprising a GLP-1 receptor agonist and a glucagon receptor agonist and an application of the composition. More specifically, the present invention provides a pharmaceutical composition comprising a pharmaceutically effective amount of the GLP-1 receptor agonist and the glucagon receptor agonist, wherein the GLP-1 receptor agonist and the glucagon receptor agonist independently form a conjugate with a hydrophilic polymer, or the GLP-1 receptor agonist and the glucagon receptor agonist jointly form a conjugate with the hydrophilic polymer.
Type:
Application
Filed:
December 28, 2016
Publication date:
May 9, 2019
Applicant:
PEGBIO CO., LTD.
Inventors:
Michael Min Xu, Wei Lv, Yinghui Zhang, Xiaosu Luo
Abstract: The invention provides a novel Exendin variant and the Exendin variant conjugate conjugating polymer thereon, the pharmaceutical composition comprising them and use of them for treating diseases such as reducing blood glucose, treating diabetes, especially Type II diabetes. The invention also provides the use of Exendin conjugate for lowering body weight.
Type:
Grant
Filed:
April 23, 2010
Date of Patent:
November 5, 2013
Assignee:
Pegbio Co., Ltd.
Inventors:
Michael M. Xu, Yongxiang Wang, Yinghui Zhang, Xiaosu Luo, Nian Gong, Lijie Zhang, Xiangjun Zhou
Abstract: The invention provides a novel Exendin variant and the Exendin variant conjugate conjugating polymer thereon, the pharmaceutical composition comprising them and use of them for treating diseases such as reducing blood glucose, treating diabetes, especially Type II diabetes. The invention also provides the use of Exendin conjugate for lowering body weight.
Type:
Application
Filed:
April 23, 2010
Publication date:
August 2, 2012
Applicant:
PEGBIO CO., LTD.
Inventors:
Michael M. Xu, Yongxiang Wang, Yinghui Zhang, Xiaosu Luo, Nian Gong, Lijie Zhang, Xiangjun Zhou